|
ABOS | Acumen Pharmaceuticals, Inc. |
|
|
ABOS | Acumen Pharmaceuticals, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.87 |
| Leverage | 34.49% |
| Market Cap | $ 107.7m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -133.0m |
| Margin | 41270.10% |
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies for the treatment of Alzheimers disease and other neurodegenerative diseases. The company is headquartered in Charlottesville, Virginia.